Patents by Inventor Benjamin SURATT

Benjamin SURATT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF MODERATE-TO-SEVERE ASTHMA BY ADMINISTERING RILZABRUTINIB
    Publication number: 20260345619
    Abstract: Methods for treating patients with moderate-to-severe asthma comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.
    Type: Application
    Filed: June 5, 2026
    Publication date: November 5, 2026
    Applicant: Principia Biopharma Inc.
    Inventors: Jessica Gereige, David Gossage, Leda Mannent, Renata Martincova, Vincent Mikol, Benjamin Suratt
  • ASTHMA TREATMENT BY BLOCKING IL-13 AND TSLP
    Publication number: 20260285965
    Abstract: The present invention provides compounds for use in the treatment of pulmonary diseases, in particular asthma, wherein said compounds bind the cytokines IL-13 and TSLP. The treatments according to the present invention can lower the level of fractional exhaled nitric oxide (FeNO) by at least 18 ppb compared to placebo. The treatments of the present invention can also reduce eosinophil count, increase FEV1 and/or reduce airway inflammation.
    Type: Application
    Filed: March 25, 2024
    Publication date: September 24, 2026
    Applicant: Sanofi
    Inventors: Annemie Deiteren, Karine Imberdis, Emmanuel Krupka, Naimish Patel, Benjamin Suratt, Heribert Staudinger
  • TREATMENT OF SOLID ORGAN TRANSPLANT SUBJECTS WITH CD28/OX40 BISPECIFIC ANTIBODIES
    Publication number: 20260092113
    Abstract: Provided herein are methods for the treatment or prevention of solid organ transplant rejection in a subject in need thereof, comprising administering to the subject a multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40.
    Type: Application
    Filed: June 13, 2025
    Publication date: April 2, 2026
    Inventors: Rami LISSILAA, Benjamin SURATT, Jessica VOSS
  • CD28/OX40 BISPECIFIC ANTIBODIES
    Publication number: 20250215102
    Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.
    Type: Application
    Filed: December 11, 2024
    Publication date: July 3, 2025
    Inventors: Gerald BESTE, Yanik BRUYNOOGHE, Klervi DESRUMEAUX, Jennifer KUEHN, Charlotte LAHOUTE, Rami LISSILAA, Alessandro MASIERO, Sevim OEZGUER BRUEDERLE, Benjamin SURATT, Emmanuelle VIGNE, Jessica VOSS
  • CD28/OX40 bispecific antibodies
    Patent number: 12195546
    Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.
    Type: Grant
    Filed: December 18, 2023
    Date of Patent: January 14, 2025
    Assignee: SANOFI
    Inventors: Gerald Beste, Yanik Bruynooghe, Klervi Desrumeaux, Jennifer Kuehn, Charlotte Lahoute, Rami Lissilaa, Alessandro Masiero, Sevim Oezguer Bruederle, Benjamin Suratt, Emmanuelle Vigne, Jessica Voss
  • CD28/OX40 BISPECIFIC ANTIBODIES
    Publication number: 20240209107
    Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.
    Type: Application
    Filed: December 18, 2023
    Publication date: June 27, 2024
    Inventors: Gerald BESTE, Klervi DESRUMEAUX, Jennifer KUEHN, Charlotte LAHOUTE, Rami LISSILAA, Sevim OEZGUER BRUEDERLE, Benjamin SURATT, Emmanuelle VIGNE, Jessica VOSS